Imatib 100mg Tablet

• Chronic Myeloid Leukemia (CML)
• Acute Lymphoblastic Leukemia (ALL)
• Gastrointestinal Stromal Tumors (GISTs)

Doctor recommend to take Imatib 100mg tablet under strict supervision as it contains common and severe side effects that are harmful to the body. Consult the doctor if any of the symptoms persist or worsen:

• Muscle cramps and pain
• Diarrhea
• Skin rash, night sweats
• Tiredness, dizziness
• Abdominal pain
• Increased weight
• Decreased RBC and WBC cells
• Headache
• Cough, Inflammation in the nose
• Fever, lack of sleep

• Heart failure
• GI disorders
• Hypothyroidism
• Liver failure
• Swelling in the body

• Swelling in the face, legs, ankles, and feet
• Nausea, vomiting

Imatib 100mg tablet should be taken at the same time every day to increase the effectiveness of the medication. Proper and correct dosage should be administered by a professional healthcare professional only. Do not overdose or skip the medication, as it may increase the risk of side effects. Consistency is key; the medicine takes several weeks or months to show results. Use it regularly as directed by the healthcare professional to get the benefit.

Imatib 100mg tablet works by inhibiting the BCR- ABL tyrosine kinase enzyme, which is responsible for the growth of cancer cells. Blocking the enzyme, it helps stop the formation of tumor cells. It also prevents the body from further growing cancer in the body. The active dose of the medication should be taken exactly as prescribed by the doctor.

• Druker, B. J. (2004). Imatinib as a paradigm of targeted therapies. Advances in cancer research, 91, 1-30. https://pubmed.ncbi.nlm.nih.gov/15327887/
• Druker, B. J., Guilhot, F., O'Brien, S. G., Gathmann, I., Kantarjian, H., Gattermann, N., ... & Larson, R. A. (2006). Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. New England Journal of Medicine, 355(23), 2408-2417. https://pubmed.ncbi.nlm.nih.gov/17151364/
• Shah, N. P. (2005). Loss of response to imatinib: mechanisms and management. ASH Education Program Book, 2005(1), 183-187. https://pubmed.ncbi.nlm.nih.gov/16304378/
• Manley, P. W., Cowan-Jacob, S. W., Buchdunger, E., Fabbro, D., Fendrich, G., Furet, P., ... & Zimmermann, J. (2002). Imatinib: a selective tyrosine kinase inhibitor. European journal of cancer, 38, S19-S27. https://pubmed.ncbi.nlm.nih.gov/12528769/
• Iqbal, N., & Iqbal, N. (2014). Imatinib: a breakthrough of targeted therapy in cancer. Chemotherapy research and practice, 2014(1), 357027. https://pubmed.ncbi.nlm.nih.gov/24963404/